Citations

Showing 10 of 108162 citations.

Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry
Berg, David D. , Barnett, Christopher F. , Kenigsberg, Benjamin B. , Papolos, Alexander , Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Bohula, Erin A. , Brennan, Joseph , Burke, James A. , Cremer, Paul , Daniels, Lori B. , DeFilippis, Andrew P. , Granger, Christopher B. , Hollenberg, Steven M. , Horowitz, James M. , Gladden, James D., Katz, Jason N. , Keeley, Ellen C. , Keller, Norma , Kontos, Michael C. , Lawler, Patrick R. , Menon, Venu , Metkus, Thomas S. , Miller, P. Elliott , Nativi-Nicolau, José , Newby, L. Kristin , Park, Jeong-Gun, Phreaner, Nicholas , Roswell, Robert O. , Schulman, Steven P. , Snell, R. Jeffrey, Solomon, Michael A. , Teuteberg, Jeffrey J. , Tymchak, Wayne , Morrow, David A. , Lawler, Patrick , Solomon, Michael A , Morrow, David A , Granger, Christopher B , Roswell, Robert O , Daniels, Lori B , Bohula, Erin A , Cremer, Paul C , Berg, David , Burke, James A., Carnicelli, Anthony , Chaudhry, Sunit‐Preet , Gerber, Daniel , Park, Jeong‐Gun , Sinha, Shashank S , Diepen, Sean van

Mayo Clinic

Circulation: Heart Failure | November 11, 2019 | Volume: 12 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.119.006635 | PMID 31707801 Get It

Background: Temporary mechanical circulatory support (MCS) devices provide hemodynamic assistance for shock refractory to pharmacological treatment. Most registries have focused on single devices or specific etiologies of shock, limiting data regarding overall practice patterns with temporary MCS in cardiac intensive care units. Methods: The CCCTN (Critical Care Cardiology Trials Network) is a multicenter network of tertiary CICUs in North America. Between September 2017 and September 2018, each center (n=16) contributed a 2-month snapshot of consecutive medical CICU admissions. Results: Of the 270 admissions using temporary MCS, 33% had acute myocardial infarction-related cardiogenic shock (CS), 31% had CS not related to acute myocardial infarction, 11% had mixed shock, and 22% had an indication other than shock. Among all 585 admissions with CS or mixed shock, 34% used temporary MCS during the CICU stay with substantial variation between centers (range: 17%–50%). The most common temporary MCS devices were intraaortic balloon pumps (72%), Impella (17%), and veno-arterial extracorporeal membrane oxygenation (11%), although intraaortic balloon pump use also varied between centers (range: 40%–100%). Patients managed with intraaortic balloon pump versus other forms of MCS (advanced MCS) had lower Sequential Organ Failure Assessment scores and less severe metabolic derangements. Illness severity was similar at high- versus low-MCS utilizing centers and at centers with more advanced MCS use. Conclusions: There is wide variation in the use of temporary MCS among patients with shock in tertiary CICUs. While hospital-level variation in temporary MCS device selection is not explained by differences in illness severity, patient-level variation appears to be related, at least in part, to illness severity.
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
Detke, Holland C. , Millen, Brian A. , Zhang, Qi , Samaan, Karen , Aurora, Sheena K. , Ailani, Jessica , Dodick, David W.

Mayo Clinic

Headache: The Journal of Head and Face Pain | November 11, 2019 | Volume: 60 | Issue: 2 | Pages: 348-359

10.1111/head.13691 | PMID 31710104 Get It

Objective To evaluate onset of effect of galcanezumab in patients with episodic migraine. Background Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related peptide and is indicated for preventive treatment of migraine. Design/Methods Data on the primary outcome measure were analyzed from 2 previously published double‐blind, Phase 3 studies (EVOLVE‐1 [N = 858] and EVOLVE‐2 [N = 915]) wherein adult patients with episodic migraine were randomized to receive monthly subcutaneous injections of galcanezumab 120 mg (with 240‐mg loading dose) or 240 mg or placebo for up to 6 months. Monthly onset of effect was defined as the earliest month at which galcanezumab achieved and subsequently maintained statistical superiority to placebo on the mean change from baseline in the number of monthly migraine headache days (MHDs). If onset occurred in Month 1, weekly onset was evaluated and defined as the earliest week at which galcanezumab statistically separated from placebo and maintained statistical separation for remaining weeks in that month. Day of onset of effect was also analyzed, as were monthly and weekly onset, for occurrence of ≥50% reduction from baseline in number of MHDs. Results For both studies, change from baseline in monthly MHDs showed a statistically significant separation of galcanezumab from placebo at Month 1 and each subsequent month (each P < .001). Analysis of the first month for both studies indicated onset of effect in the first week, with galcanezumab‐treated patients having significantly higher odds of having fewer MHDs in the first week (odds ratio [95% confidence interval] for EVOLVE‐1, 2.71 [2.00, 3.66], and for EVOLVE‐2, 2.88 [2.16, 3.86]; both P < .001) and each subsequent week compared with placebo‐treated patients ( P ≤ .004). Daily analysis showed onset of effect at Day 1 (first day after injection day). Galcanezumab also demonstrated superiority to placebo on occurrence of ≥50% reduction in MHDs starting at Week 1 (percentage of patients with 50% response in galcanezumab group vs placebo group for EVOLVE‐1, 54.3% vs 32.4% [ P < .001], and for EVOLVE‐2, 59.4% vs 38.0% [ P < .001]). Conclusion Rapid onset of preventive effect on the first day after injection of galcanezumab was confirmed in both studies of episodic migraine.
Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer
Madamsetty, Vijay Sagar , Pal, Krishnendu , Keshavan, Sandeep , Caulfield, Thomas R. , Dutta, Shamit K., Wang, Enfeng , Fadeel, Bengt , Caulfield, Thomas R , Pal, Krishnendu , Madamsetty, Vijay S , Mukhopadhyay, Debabrata

Mayo Clinic

Nanoscale | November 11, 2019 | Volume: 11 | Issue: 45 | Pages: 22006-22018

10.1039/c9nr05478b | PMID 31710073 Get It

Schematic representation demonstrating the fabrication and in vivo evaluation of an immune-modulatory nano-formulation consisting of irinotecan and curcumin in immune-competent mouse models of pancreatic adenocarcinoma.
Editorial: evolving histological assessment of NASH. Authors' reply
Pai, Rish K. , Feagan, Brian G. , Parker, Claire E. , Jairath, Vipul , Loomba, Rohit , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Loomba, Rohit , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 11, 2019 | Volume: 50 | Issue: 11-12 | Pages: 1245-1246

10.1111/apt.15570 | PMID 31709613 Get It

LINKED CONTENTThis article is linked to Pai et al and Rowe papers. To view these articles, visit https://doi.org/10.1111/apt.15503 and https://doi.org/10.1111/apt.15537.
Tumour-bowel fistula as a possible complication of pazopanib therapy in retroperitoneal leiomyosarcoma
Pereira, Rodrigo Otavio Lami , Patel, Payal R. , Sanghavi, Devang , Sanghavi, Devang K., Guru, Pramod

Mayo Clinic

BMJ Case Reports | November 11, 2019 | Volume: 12 | Issue: 11 | Pages: e230727

10.1136/bcr-2019-230727 | PMID 31712231 Get It

Pazopanib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) that inhibits the vascular endothelial growth factor receptor A pathway and has the potential to cause ischaemic bowel changes, including perforation. Here we report a case of a 51-year-old man with large, metastatic, retroperitoneal leiomyosarcoma that developed a tumour-bowel fistula after 4 weeks of pazopanib therapy. He presented to the emergency department with sepsis and 1-week history of worsening fever, chills, nausea and diarrhoea. Abdominal CT findings of mesenteric and portal vein gas, commonly found in mesenteric ischaemia and VEGFR modulator-induced bowel toxicity, provided evidence for the causal relation. Unfortunately, the case was not amenable to surgery and patient succumbed to the illness.
Thiol‐ene Hydrogels for Local Delivery of PTH for Bone Regeneration in Critical Size defects
Wojda, Samantha J. , Marozas, Ian A., Yaszemski, Michael J. , Donahue, Seth W. , Anseth, Kristi S.

Mayo Clinic

Journal of Orthopaedic Research | November 11, 2019 | Volume: 38 | Issue: 3 | Pages: 536-544

10.1002/jor.24502 | PMID 31709588 Get It

ABSTRACTNeither allograft nor commercially available bone graft substitutes provide the same quality of bone healing as autograft. Incorporation of bioactive molecules like parathyroid hormone (PTH) within bone graft substitute materials may provide similar, if not better treatment options to grafting. The goal of this work was to develop a biomaterial system for the local delivery of PTH to large bone defects for promoting bone regeneration. PTH was loaded in a thiol‐ene hydrogel at several concentrations and polymerized in and around an osteoconductive poly(propylene fumarate) (PPF) scaffold. PTH was shown to be bioactive when released from the hydrogel for up to 21 days. Eighty percent of the PTH was released by day 3 with the remaining 20% released by day 14. Bone healing was quantified in rat critical size femoral defects that were treated with hydrogel/PPF and 0, 1, 3, 10, or 30 µg of PTH. Although complete osseous healing was not observed in all samples in any one treatment group, all samples in the 10 µg PTH group were bridged fully by bone or a combination of bone and cartilage containing hypertrophic chondrocytes and endochondral ossification. Outcome measures indicated improved defect bridging by a combination of bony and cartilaginous tissue in the 10 μg treatment group compared with empty bone defects and defects treated with only hydrogel/PPF (i.e., without PTH). Given the tailorability of the hydrogel, future studies will investigate the effects of prolonged gradual PTH release on bone healing. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:536–544, 2020
Spatial Accuracy of a Clinically Established Noninvasive Electrocardiographic Imaging System for the Detection of Focal Activation in an Intact Porcine Model
Hohmann, Stephan , Rettmann, Maryam E. , Borenstein, Anna, Wang, Songyun , Suzuki, Atsushi , Michalak, Gregory J. , Monahan, Kristi H. , Parker, Kay D., Newman, Laura K. , Packer, Douglas L. , Konishi, Hiroki, Newman, L Katie, Hohmann, Stephan , Konishi, Hiroki

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 11, 2019 | Volume: 12 | Issue: 11 | Pages: No page available

10.1161/circep.119.007570 | PMID 31707808 Get It

Background: Noninvasive electrocardiographic imaging (ECGi) is used clinically to map arrhythmias before ablation. Despite its clinical use, validation data regarding the accuracy of the system for the identification of arrhythmia foci is limited. Methods: Nine pigs underwent closed-chest placement of endocardial fiducial markers, computed tomography, and pacing in all cardiac chambers with ECGi acquisition. Pacing location was reconstructed from biplane fluoroscopy and registered to the computed tomography using the fiducials. A blinded investigator predicted the pacing location from the ECGi data, and the distance to the true pacing catheter tip location was calculated. Results: A total of 109 endocardial and 9 epicardial locations were paced in 9 pigs. ECGi predicted the correct chamber of origin in 85% of atrial and 92% of ventricular sites. Lateral locations were predicted in the correct chamber more often than septal locations (97% versus 79%, P =0.01). Absolute distances in space between the true and predicted pacing locations were 20.7 (13.8–25.6) mm (median and [first–third] quartile). Distances were not significantly different across cardiac chambers. Conclusions: The ECGi system is able to correctly identify the chamber of origin for focal activation in the vast majority of cases. Determination of the true site of origin is possible with sufficient accuracy with consideration of these error estimates.
Positive HLA‐B27 and sacroiliitis is not always spondyloarthritis
Aslam, Fawad , Chivers, F. Spencer, Doshi, Krupa , Chang‐Miller, April, Chivers, Frederick Spencer, Doshi, Krupa B , Aslam, Fawad

Mayo Clinic

International Journal of Rheumatic Diseases | November 11, 2019 | Volume: 22 | Issue: 12 | Pages: 2213-2217

10.1111/1756-185x.13738 | PMID 31709741 Get It

AbstractA 36‐year‐old man was treated for several years with multiple agents for ankylosing spondylitis based on positive human leukocyte antigen‐B27 and sacroiliitis. He was also diagnosed with osteoporosis and hypophosphatemia. Over these years, from being an avid runner, he became dependent on a walker for ambulation. The lack of treatment response and the low phosphorus were clues that eventually led to a diagnosis of tumor‐induced osteomalacia. This case discusses the importance of not solely relying on genetic markers and sacroiliitis for diagnosing ankylosing spondylitis as other conditions can cause similar presentations.
Multicenter Analysis of Dosing Protocols for Sotalol Initiation
Biswas, Minakshi , Levy, Andrew , Weber, Rachel, Tarakji, Khaldoun G. , Chung, Mina K. , Newton‐Cheh, Christopher , Rosenberg, Michael A. , Rosenberg, Michael A , Noseworthy, Peter A.

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | November 10, 2019 | Volume: 25 | Issue: 3 | Pages: 212-218

10.1177/1074248419887710 | PMID 31707834 Get It

Sotalol, a Vaughan-Williams Class III antiarrhythmic medication, is used to manage atrial arrhythmias. Due to its QT-prolonging effect and subsequent increased risk of torsade de pointes, many centers admit patients during the initial dosing period. Despite its widespread use, little information is available regarding dosing protocols during this period. In this multicenter investigation, dosing protocols in patients initiating sotalol therapy were examined to identify predictors of successful sotalol initiation. Over a 4-year period, patients admitted to 5 hospitals in the United States for inpatient telemetry monitoring during initiation for nonresearch purposes were enrolled. A 3-day course of 5 of 6 doses of sotalol was considered successful completion of the loading protocol. Of the 213 enrolled patients, over 90% were successfully discharged on sotalol. Significant bradycardia, ineffectiveness, and excessive QT prolongation were reasons for failed completion. Absence of a dose adjustment was a strong predictor of successful initiation (odds ratio: 6.6, 95% confidence interval: 1.3-32.7, P = .02). Hypertension, use of a calcium channel blocker, use of a separate β-blocker, and presence of a pacemaker were predictors of dose adjustments. Marginal structural models (ie, inverse probability weighting based on probability of a dose adjustment) verified that these factors also predicted successful initiation via preventing any dose adjustment and suggests that considering these factors may result in a higher likelihood of successful initiation in future investigations. In conclusion, we found that the majority of patients admitted for sotalol initiation are successfully discharged on the medication. The study findings suggest that factors predicting need for dose adjustment can be used to identify patients who could undergo outpatient initiation. Prospective studies are needed to verify this approach.